Sanctuary Advisors LLC Purchases 2,181 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Sanctuary Advisors LLC lifted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 91.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,558 shares of the biopharmaceutical company's stock after acquiring an additional 2,181 shares during the period. Sanctuary Advisors LLC's holdings in Alnylam Pharmaceuticals were worth $1,254,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Teachers Retirement System of The State of Kentucky boosted its position in shares of Alnylam Pharmaceuticals by 4.5% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 34,713 shares of the biopharmaceutical company's stock valued at $9,547,000 after buying an additional 1,500 shares during the last quarter. Toronto Dominion Bank boosted its holdings in shares of Alnylam Pharmaceuticals by 27.3% during the 3rd quarter. Toronto Dominion Bank now owns 15,466 shares of the biopharmaceutical company's stock valued at $4,254,000 after acquiring an additional 3,315 shares during the last quarter. Coldstream Capital Management Inc. grew its stake in shares of Alnylam Pharmaceuticals by 43.7% in the third quarter. Coldstream Capital Management Inc. now owns 1,211 shares of the biopharmaceutical company's stock worth $329,000 after acquiring an additional 368 shares during the period. Geode Capital Management LLC raised its holdings in shares of Alnylam Pharmaceuticals by 3.2% during the third quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company's stock valued at $589,209,000 after purchasing an additional 66,928 shares during the last quarter. Finally, Prestige Wealth Management Group LLC lifted its position in Alnylam Pharmaceuticals by 65.8% during the third quarter. Prestige Wealth Management Group LLC now owns 451 shares of the biopharmaceutical company's stock valued at $124,000 after purchasing an additional 179 shares during the period. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Trading Up 2.8 %

Shares of NASDAQ:ALNY traded up $6.57 during trading on Friday, reaching $245.44. The company's stock had a trading volume of 1,648,262 shares, compared to its average volume of 861,361. The firm's 50 day simple moving average is $263.83 and its two-hundred day simple moving average is $251.40. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The stock has a market capitalization of $31.66 billion, a PE ratio of -93.68 and a beta of 0.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to analysts' expectations of $532.91 million. The business's revenue was down 33.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.15 earnings per share. On average, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have weighed in on ALNY. Canaccord Genuity Group boosted their target price on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a "buy" rating in a research note on Friday, November 1st. TD Cowen boosted their price objective on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a "buy" rating in a research report on Monday, October 21st. Raymond James raised their target price on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an "outperform" rating in a report on Friday, November 1st. JPMorgan Chase & Co. boosted their price target on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a "neutral" rating in a report on Monday, August 26th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $298.09.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CMO Pushkal Garg sold 1,752 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $251.00, for a total transaction of $439,752.00. Following the completion of the sale, the chief marketing officer now directly owns 15,705 shares in the company, valued at approximately $3,941,955. This trade represents a 10.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Tolga Tanguler sold 1,469 shares of the company's stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the transaction, the executive vice president now owns 13,191 shares in the company, valued at approximately $3,310,677.18. The trade was a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,122 shares of company stock worth $2,540,455. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.